According to EurekaAlert, Novo Biosciences Inc., a spinoff of the MDI Biological Laboratory in Bar Harbor, Maine, has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack. “We believe MSI-1436 has enormous potential,” said Kevin Strange, Ph.D., CEO of Novo Biosciences and president of the MDI Biological Laboratory. “No drug now exists to treat heart attack. Heart disease is the the world’s leading killer. In order to advance MSI-1436 into clinical trials, we need to first test its effectiveness in a large animal model. We are deeply grateful to the National Heart, Lung, and Blood Institute for making this possible.” Read more
Novo Biosciences Receives Federal Grant to Advance Potential Heart Drug
Related Posts
Maine’s first mobile biolab starts tour of rural schools in Fort Kent
FORT KENT, Maine — Fort Kent middle schoolers are the state’s first students to learn at the newly unveiled Maine Mobile Biolab, a 50-foot,...
UMaine Augusta’s $1.75M medical lab training facility doubles student capacity
Anew medical lab training facility on the campus of University of Maine Augusta is nearly six times larger than an off-campus space...
UNE receives grant to research state-threatened animal
The University of New England has received a grant from the Maine Department of Inland Fisheries and Wildlife to study one...